Troubled Dendreon pursues new biomarkers for Provenge; Exagen lands $25M loan for rheumatology tests;

> Despite falling sales and a so-far failed effort to find a buyer, Dendreon ($DNDN) continues to pursue new research into biomarkers that could be used to guide the use of Provenge. Story

> Exagen Diagnostics has nailed down a loan for up to $25 million that will help the company expand sales efforts for its rheumatology tests. Report

> A new report from Decision Resources concludes that while biomarkers have been most useful in oncology, they are also playing a growing role for chronic conditions. Release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.